Page last updated: 2024-08-24

nelfinavir and lopinavir

nelfinavir has been researched along with lopinavir in 117 studies

Research

Studies (117)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	70 (59.83)	29.6817
2010's	37 (31.62)	24.3611
2020's	10 (8.55)	2.80

Authors

Authors	Studies
Abbenante, G; Fairlie, DP; Leung, D	1
Danielson, UH; Shuman, CF; Vrang, L	1
Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; King, NM; Maes, LJ; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Vendeville, S; Verschueren, WG; Wigerinck, PB	1
Bertucci, C; Cimitan, S; Danielson, UH; Lindgren, MT	1
Brieger, M; Furfine, ES; Hazen, RJ; Kaldor, I; Miller, JF; Reynolds, D; Sherrill, RG; Spaltenstein, A	1
Dansette, PM; Fontana, E; Poli, SM	1
Andrews, CW; Brieger, M; Furfine, ES; Hale, MR; Hanlon, MH; Hazen, RJ; Kaldor, I; McLean, EW; Miller, JF; Reynolds, D; Sammond, DM; Sherrill, RG; Spaltenstein, A; Tung, R; Turner, EM; Xu, RX	1
Agbandje-McKenna, M; Clemente, JC; Coman, RM; Dunn, BM; Goodenow, MM; Govindasamy, L; Janka, LK; Jeung, JA; Leelamanit, W; McKenna, R; Nukoolkarn, S; Thiaville, MM	1
Dekhtyar, T; Kempf, DJ; Lu, L; Mo, H; Molla, A; Parkin, N; Stewart, KD	1
Brenner, BG; Moisi, D; Ntemgwa, M; Oliveira, M; Wainberg, MA	1
Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT	1
Bernstein, B; Dekhtyar, T; Gao, F; Hanna, GJ; Kempf, D; Koev, G; Lu, L; Lu, X; Masse, S; Mo, H; Molla, A	1
Boone, L; Craig, C; Ferris, R; Furfine, E; Griffin, P; Hale, M; Hanlon, M; Harvey, R; Hazen, R; Kaldor, I; Miller, J; Ray, J; Samano, V; Spaltenstein, A; St Clair, M; Tung, R; Yates, P	1
Dandache, S; Parkin, N; Schapiro, JM; Sévigny, G; Stranix, BR; Wainberg, MA; Wu, JJ; Yelle, J	1
Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L	1
Hayashi, H; Mimoto, T; Nojima, S; Shintani, M; Takaku, H; Terashima, K	1
DeGoey, DA; Dekhtyar, T; Flosi, WJ; Grampovnik, DJ; Kempf, DJ; Klein, LL; Lu, L; Masse, S; Molla, A; Ng, TI	1
Bénard, A; Brun-Vézinet, F; Campa, P; Chêne, G; Collin, G; Damond, F; Desbois, D; Descamps, D; Matheron, S; Peytavin, G; Roquebert, B	1
Chen, L; Chen, X; He, Z; Peng, N; Qin, L; You, J	1
Brynda, J; Cígler, P; Fanfrlík, J; Grantz Sasková, K; Grüner, B; Konvalinka, J; Kozísek, M; Král, V; Lepsík, M; Plesek, J; Pokorná, J; Rezácová, P; Václavíková, J	1
Amano, M; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Mitsuya, H; Nakata, H; Nakayama, M; Ogata-Aoki, H	1
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E	1
Chen, YC; Dumond, JB; Fiscus, SA; Horton, AL; Kashuba, AD; Patterson, KB; Rezk, NL; Tappouni, HL; Tien, HC; Vourvahis, M; Yeh, RF	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Lisovsky, I; Martinez-Cajas, JL; Moisi, D; Oliveira, M; Schader, SM; Wainberg, MA	1
Amano, M; Anderson, DD; Aoki, M; Das, D; Ghosh, AK; Koh, Y; Kulkarni, S; Mitsuya, H; Tojo, Y	1
Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP	1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ	1
Cane, PA; Kolli, M; Myers, RE; Parry, CM; Pillay, D; Schiffer, C	1
Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Al-Abed, Y; Altiti, A; Bloom, O; Cheng, KF; Coleman, TR; Crawford, JM; Diamond, B; Grant, C; He, M; Jeganathan, V; Kowal, C; Meurice, N; Papatheodorou, A; Sun, S; VanPatten, S; Volpe, BT	1
Anderson, KS; Cabeza de Vaca, I; Deshmukh, M; Ghahremanpour, MM; Ippolito, JA; Jorgensen, WL; Liosi, ME; Tirado-Rives, J; Zhang, CH	1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF	1
Gulick, R	1
Gantke, B; Kuschak, D; Mauss, S; Schmutz, G	1
Jaillon, P; Poirier, JM; Robidou, P	2
Jain, RG; Lenhard, JM	1
Edno-Mcheik, L; Lagrange, F; Molimard, M; Moore, N; Péhourcq, F; Titier, K	1
Hammer, SM	1
Arribas, J; Beall, G; Bernstein, B; Brun, S; Japour, A; Johnson, D; Johnson, M; King, M; Lalonde, R; Ruane, P; Sun, E; Walmsley, S	1
DiFrancesco, R; Frerichs, VA; Keil, K; Morse, G	1
Bartlett, JG; Celentano, DD; Lai, H; Lai, S; Lima, JA; Margolick, J; Ren, S; Vlahov, D	1
Albert, J; Blaxhult, A; Brandin, E; Broström, C; Gisslen, M; Gyllensten, K; Hagberg, L; Lindborg, L; Tuvesson, B	1
Ailhaud, G; Azoulay, S; Dani, C; Duval, D; Guedj, R; Vernochet, C	1
Bauer, E; Bernstein, B; Brun, S; Cernohous, P; Gu, K; Hsu, A; Kempf, DJ; King, MS; Moseley, J; Sun, E	1
Bini, T; Bongiovanni, M; Chiesa, E; Monforte, Ad	1
DeGoey, DA; Randolph, JT	1
Bernstein, BM; Brun, SC; Cernohous, P; Feinberg, J; King, MS; Montaner, JS; Sanne, I; Sherer, R; Sun, E; Walmsley, SL	1
DeSilva, KE; Guest, JL; Rimland, D; Ruffin, C; Tschampa, JM	1
Chaisson, RE; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL	1
Gerber, JG; Wyles, DL	1
Alvaro-Meca, A; de José, MI; Gurbindo, MD; Martin-Fontelos, P; Muñoz-Fernández, MA; Ramos, JT; Resino, S	1
Brun, SC; Kempf, DJ; King, MS	1
Brun, S; Cernohous, P; Da Silva, B; Omachi, JH; Rouster, SD; Sherman, KE; Shire, NJ	1
Afonso, A; Aguiar, RS; Arruda, MB; Brindeiro, PA; Brindeiro, RM; Gonzalez, LMF; Soares, MA; Tanuri, A	1
Crane, HM; Kitahata, MM; Van Rompaey, SE	1
Bacheler, L; Corral, A; de Mendoza, C; Pattery, T; Soriano, V; Valer, L	1
Bates, DE; Herman, RJ	1
Harris, M; Hogg, RS; Montaner, JS; Moore, DM; Wood, E; Yip, B	1
de Hoon, J; Van Wijngaerden, E; Verbesselt, R	1
Biollaz, J; Buclin, T; Colombo, S; Décosterd, LA; Eap, CB; Furrer, H; Lee, BL; Telenti, A	1
Balfour, HH; Brundage, RC; Vezina, HE; Weller, DR	1
Alvanzo, A; Baker, J; Friedland, G; Jatlow, P; McCance-Katz, EF; Moody, DE; Morse, GD; Pade, P; Rainey, PM; Smith, PF	1
Choi, SO; Kashuba, AD; Rezk, NL	1
Chrysos, G; Kokkoris, S; Kontochristopoulos, G; Mikros, S; Pastelli, A	1
Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R	1
Alonso-Socas, Mdel M; Delgado, R; García-Bujalance, S; Garriga, C; Menéndez-Arias, L; Nájera, R; Pérez-Elías, MJ; Pumarola, T; Ruiz, L	1
Abbara, C; Barrail, A; Boissonnas, A; Bonhomme-Faivre, L; Duclos-Vallée, JC; Samuel, D; Taburet, AM; Teicher, E; Vincent, I; Vittecoq, D	1
Antinori, A; Baxter, J; Cauda, R; Clevenbergh, P; Colafigli, M; De Luca, A; Giambenedetto, SD; Perno, CF; Prosperi, M; Ruiz, L; Trotta, MP	1
Burri, M; Nadal, D; Rode, R; Rudin, C; Shen, Y	1
Fulco, PP; Higginson, RT; Zingone, MM	1
Amici, R; Baroncelli, S; Cusato, M; Floridia, M; Galluzzo, CM; Molinari, A; Pinnetti, C; Pirillo, MF; Regazzi, M; Sabbatini, F; Tamburrini, E; Villani, P	1
Louis, JM; Sayer, JM	1
Boesmans, D; Di Fazio, V; Elens, L; Haufroid, V; Vanbinst, R; Veriter, S; Wallemacq, P	1
Hao, C; Liu, X; Xiu, Z	1
Altoé, EF; Alves, CR; Branquinha, MH; Britto, C; d'Avila-Levy, CM; Marinho, FA; Motta, MC; Santos, AL; Santos, LO; Vitório, BS	1
Anceschi, MM; Ascenzi, P; Ivanovic, J; Mattia, E; Narciso, P; Nicastri, E; Notari, S; Pisani, G; Pucillo, LP; Signore, F; Tempestilli, M; Vallone, C	1
Chandrasekar, S; Jayakanthan, M; Mathur, PP; Muthukumaran, J	1
Fessel, WJ; Hellinger, J; Kaufman, D; Rhee, SY; Ruane, P; Shafer, RW; Shirvani, V; Taylor, J; Towner, W; Troia, P; Zolopa, A	1
Baki, L; Baumgarten, CM; Deng, W; Yin, J; Zhou, H	1
Antoine, B; Capeau, J; Chapron, C; Kadiri, S; Leroyer, S; Quette, J; Vatier, C	1
Alteri, C; Cella, E; Ciccozzi, M; Ciotti, M; Drašković, N; Fabeni, L; Lai, A; Laušević, D; Lo Presti, A; Marjanovic, A; Mugoša, B; Santoro, MM; Vratnica, Z; Vujošević, D; Zehender, G	1
de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C	1
Andrews, S; Carlson, GA; Hanamsagar, R; Huang, Y; Ikezu, T; Kiyota, T; Lan, X; Peng, H; Swindells, S; Zheng, JC	1
Anu, R; Cauda, R; De Donatis, GM; Gillet, JP; Gottesman, MM; Handley, M; Lucia, MB; Wu, CP	1
Nsanzabana, C; Rosenthal, PJ	1
Asahchop, EL; Brenner, BG; Doualla-Bell, F; Grossman, Z; Lisovsky, I; Martinez-Cajas, JL; Mendelson, E; Moisi, D; Oliveira, M; Wainberg, MA	1
Boer, K; Godfried, MH; Nellen, J; Scherpbier, H; van Hoog, S	1
Liu, L; Unadkat, JD	1
Azoulay, S; Dani, C; Darini, CY; Drici, MD; Hofman, P; Ladoux, A; Martin, P; Obba, S	1
Bader, J; Driessen, C; Kraus, M; Müller-Ide, H; Overkleeft, H; Rückrich, T	1
Brandmann, M; Dringen, R; Hohnholt, MC; Petters, C	1
Anderson, AM; Coffie, PA; Dabis, F; Eholie, SP; Ekouevi, DK; Gottlieb, GS; Tchounga, BK; Tegbe, J; Vitoria, M	1
Branquinha, MH; D Avila-Levy, CM; Menna-Barreto, RF; Sangenito, LS; Santos, AL	1
Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K	1
Ande, A; Kumar, A; Kumar, S; Li, J; Li, W; Nookala, AR; Vaidya, NK; Wang, L	1
Barr, E; Davies, J; Forster, JE; Kinzie, K; Levin, MJ; McFarland, EJ; Pappas, J; Paul, S; Smith, C; Weinberg, A	1
Branquinha, MH; d'Avila-Levy, CM; Sangenito, LS; Santos, ALS	1
Branquinha, MH; d'Avila-Levy, CM; de Guedes, AA; Gonçalves, DS; Sangenito, LS; Santos, ALS; Seabra, SH	1
Bader, J; Besse, A; Besse, L; Driessen, C; Kraus, M; Morgan, GJ; Overkleeft, HS; Rasche, L; Stolze, SC; Weinhold, N	1
Barrow, G; Camacho, R; Carmona, S; Grant, PM; Gupta, RK; Hamers, RL; Harrigan, PR; Jordan, MR; Kantor, R; Katzenstein, DA; Kuritzkes, DR; Maldarelli, F; Otelea, D; Paredes, R; Schapiro, JM; Shafer, RW; Tzou, PL; van Zyl, G; Wallis, CL	1
Abt, D; Bader, J; Besse, A; Besse, L; Driessen, C; Engeler, DS; Kraus, M; Schmid, HP; Sedlarikova, L; Silzle, T; Slaby, O; Vodinska, M	1
Branquinha, MH; d'Avila-Levy, CM; Menna-Barreto, RFS; Oliveira, AC; Sangenito, LS; Santos, ALS	1
Kim, JY; Lee, BM; Park, YJ; Yoon, S	1
Avril, T; Bolsée, J; Charpak-Amikam, Y; Chevet, E; Dipta, P; Gilham, DE; Mahameed, M; Mandelboim, O; Obiedat, A; Seidel, E; Shmuel, M; Springuel, L; Stern-Ginossar, N; Tai-Schmiedel, J; Tirosh, B	1
Barlow, A; Barlow, B; Claassen, CW; Heavner, JJ; Heavner, MS; Landolf, KM; Yeung, SYA	1
Hirano, Y; Komatsu, TS; Koyama, YM; Morimoto, G; Ohno, Y; Okimoto, N; Taiji, M	1
Bissaro, M; Bolcato, G; Moro, S; Pavan, M; Sturlese, M	1
Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X	1
Li, HY; Liu, WT; Sun, HB; Wang, W; Wu, SL; Yu, YX; Zhang, LL	1
Abdelnabi, R; Annaert, PP; Augustijns, PF; Cambier, S; Chatterjee, AK; Coelmont, L; Dallmeier, K; De Jonghe, S; Delang, L; Foo, CS; Gouwy, M; Heylen, E; Jochmans, D; Kaptein, SJF; Leyssen, P; Mols, R; Neyts, J; Proost, P; Rocha-Pereira, J; Ter Horst, S; van Laer, C; Vandooren, J; Vangeel, L; Vergote, V; Weynand, B; Zhang, X	1
Baniwal, P; Inbaraj, BS; Kashyap, P; Kumar, S; Sharma, M; Shikha, D; Singh, N; Sridhar, K; Thakur, M; Yadav, YS	1

Reviews

9 review(s) available for nelfinavir and lopinavir

Article	Year
Protease inhibitors: current status and future prospects. Journal of medicinal chemistry, 2000, Feb-10, Volume: 43, Issue:3 Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors	2000
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Current drug metabolism, 2005, Volume: 6, Issue:5 Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic	2005
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. Journal of medicinal chemistry, 2012, Jun-14, Volume: 55, Issue:11 Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors	2012
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. European journal of medicinal chemistry, 2022, Jul-05, Volume: 237 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells	2022
Peptidomimetic inhibitors of HIV protease. Current topics in medicinal chemistry, 2004, Volume: 4, Issue:10 Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane	2004
Quality control of protease inhibitors. Journal of pharmaceutical sciences, 2008, Volume: 97, Issue:6 Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides	2008
Antiretroviral therapy response among HIV-2 infected patients: a systematic review. BMC infectious diseases, 2014, Aug-26, Volume: 14 Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Female; HIV Infections; HIV-2; Humans; Indinavir; Lopinavir; Male; Middle Aged; Nelfinavir; Ritonavir; Treatment Outcome	2014
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy, 2020, Volume: 40, Issue:5 Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunomodulation; Interferon-alpha; Lopinavir; Nelfinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ribavirin; Ritonavir; SARS-CoV-2; Sulfonamides; Thiazoles	2020
In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease. Molecules (Basel, Switzerland), 2022, Sep-27, Volume: 27, Issue:19 Topics: Antiviral Agents; COVID-19 Drug Treatment; Diosmin; Flavonoids; Hesperidin; Humans; Lopinavir; Molecular Docking Simulation; Nelfinavir; Ritonavir; Rutin; SARS-CoV-2; Spike Glycoprotein, Coronavirus	2022

Trials

8 trial(s) available for nelfinavir and lopinavir

Article	Year
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. The New England journal of medicine, 2002, Jun-27, Volume: 346, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nelfinavir; Proportional Hazards Models; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Survival Analysis; Viral Load	2002
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. The Journal of infectious diseases, 2004, Jan-01, Volume: 189, Issue:1 Topics: Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Global Health; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Mutation; Nelfinavir; Patient Compliance; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Time Factors; Viral Load	2004
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. The Journal of infectious diseases, 2004, Jul-15, Volume: 190, Issue:2 Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Nelfinavir; Predictive Value of Tests; Pyrimidinones; Risk Factors; Ritonavir; RNA, Viral; Sex Characteristics; Stavudine; Viral Load	2004
Lopinavir/r versus nelfinavir as salvage therapy. The Pediatric infectious disease journal, 2005, Volume: 24, Issue:4 Topics: Child; Child, Preschool; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lopinavir; Nelfinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Salvage Therapy; Viral Load	2005
Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. The Journal of infectious diseases, 2005, Jun-15, Volume: 191, Issue:12 Topics: Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Odds Ratio; Patient Compliance; Pyrimidinones; Risk Factors; Ritonavir; RNA, Viral; Viral Load	2005
Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Oct-15, Volume: 41, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; RNA, Viral; Viral Load	2005
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clinical pharmacokinetics, 2007, Volume: 46, Issue:11 Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Female; Graft Rejection; Half-Life; Hepatitis C; HIV; HIV Infections; Humans; Liver Transplantation; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Tacrolimus; Viral Load	2007
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. Antiviral therapy, 2010, Volume: 15, Issue:8 Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load	2010

Other Studies

100 other study(ies) available for nelfinavir and lopinavir

Article	Year
Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data. Journal of medicinal chemistry, 2004, Nov-18, Volume: 47, Issue:24 Topics: Biosensing Techniques; Cells, Cultured; Cluster Analysis; HIV Protease; HIV Protease Inhibitors; HIV-1; Kinetics; Principal Component Analysis; Quantitative Structure-Activity Relationship; Virus Replication	2004
Design of HIV-1 protease inhibitors active on multidrug-resistant virus. Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6 Topics: Animals; Benzoxazoles; Binding Sites; Calorimetry; Cell Line; Crystallography, X-Ray; Dogs; Drug Resistance, Multiple, Viral; Drug Stability; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Rats; Rats, Wistar; Sulfonamides; Thermodynamics; Thiazoles	2005
Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions. Journal of medicinal chemistry, 2005, May-19, Volume: 48, Issue:10 Topics: Absorption; Anti-HIV Agents; Antineoplastic Agents; Binding Sites; Biosensing Techniques; Blood Proteins; HIV Protease; HIV Protease Inhibitors; Humans; Kinetics; Lipids; Membranes, Artificial; Orosomucoid; Serum Albumin; Surface Plasmon Resonance; Taxoids	2005
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles. Bioorganic & medicinal chemistry letters, 2005, Aug-01, Volume: 15, Issue:15 Topics: Animals; Anti-HIV Agents; Dogs; Drug Resistance, Multiple, Viral; HIV; HIV Protease Inhibitors; Inhibitory Concentration 50; Mutation; Rats; Structure-Activity Relationship; Virus Replication	2005
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. Bioorganic & medicinal chemistry letters, 2006, Apr-01, Volume: 16, Issue:7 Topics: HIV Protease Inhibitors; Molecular Structure; Sulfonamides	2006
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. Biochemistry, 2006, May-02, Volume: 45, Issue:17 Topics: Amino Acid Substitution; Atazanavir Sulfate; Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; Hydrophobic and Hydrophilic Interactions; Kinetics; Models, Molecular; Oligopeptides; Polymorphism, Genetic; Pyridines; Structure-Activity Relationship	2006
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2 Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genes, gag; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation; Nelfinavir; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Virus Replication	2007
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2 Topics: Amino Acid Sequence; Carbamates; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Polymorphism, Genetic; Pyridines; Pyrones; Sulfonamides	2007
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:6 Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication	2007
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9 Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Line; Cytopathogenic Effect, Viral; Drug Resistance, Viral; HIV Core Protein p24; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Molecular Sequence Data; Mutagenesis, Site-Directed; Phenotype; Pyrimidinones; RNA-Directed DNA Polymerase; Virus Replication	2007
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9 Topics: Algorithms; Anti-Retroviral Agents; Benzodioxoles; Blood Proteins; Carbamates; Cell Line; Drug Resistance, Viral; HeLa Cells; HIV Protease Inhibitors; HIV-1; Humans; Orosomucoid; Phenotype; Serum; Serum Albumin; Tyrosine	2007
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:11 Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Cell Survival; Drug Resistance, Viral; Genotype; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Mutation; Phenotype; Sulfonamides; Viral Proteins	2007
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:10 Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir	2007
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure. Bioorganic & medicinal chemistry, 2008, Feb-01, Volume: 16, Issue:3 Topics: Animals; Dogs; Drug Design; Hepatocytes; HIV Protease Inhibitors; HIV-1; Humans; Molecular Structure; Mutation; Phenylbutyrates; Sensitivity and Specificity; Structure-Activity Relationship	2008
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4 Topics: Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Selection, Genetic; Serial Passage	2008
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4 Topics: Darunavir; HIV Protease; HIV Protease Inhibitors; HIV-2; Humans; Inhibitory Concentration 50; Lopinavir; Microbial Sensitivity Tests; Phenotype; Pyrimidinones; Saquinavir; Sulfonamides	2008
Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:7 Topics: Animals; Antimalarials; Atazanavir Sulfate; Chloroquine; Drug Resistance; Drug Synergism; Female; HIV Protease Inhibitors; Humans; In Vitro Techniques; Lopinavir; Malaria; Mice; Nelfinavir; Oligopeptides; Plasmodium chabaudi; Plasmodium falciparum; Pyridines; Pyrimidinones; Ritonavir; Saquinavir	2008
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance. Journal of medicinal chemistry, 2008, Aug-14, Volume: 51, Issue:15 Topics: Boron Compounds; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Metals; Models, Molecular; Molecular Structure; Mutation	2008
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3 Topics: Amino Acid Sequence; Carbamates; Cyclopentanes; Dose-Response Relationship, Drug; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Sequence Data; Molecular Structure; Sulfonamides	2009
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorganic & medicinal chemistry, 2009, Jan-15, Volume: 17, Issue:2 Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship	2009
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:6 Topics: Acquired Immunodeficiency Syndrome; Adult; Amniotic Fluid; Anti-HIV Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Fetal Blood; Genitalia, Female; HIV-1; Humans; Hydrocortisone; Pregnancy; Pregnancy Complications, Infectious; RNA, Viral	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:7 Topics: Anti-HIV Agents; Atazanavir Sulfate; Cell Line; Cells, Cultured; Codon; Genotype; HIV Infections; HIV Protease; HIV-1; Humans; Lopinavir; Nelfinavir; Oligopeptides; Polymorphism, Genetic; Pyridines; Pyrimidinones	2010
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:8 Topics: Cell Line; Dimerization; Drug Resistance, Multiple, Viral; Furans; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Macrocyclic Compounds; Microbial Sensitivity Tests; Models, Molecular; Structure-Activity Relationship; Virus Replication	2010
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides	2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics	2010
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:3 Topics: Cell Line; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; gag Gene Products, Human Immunodeficiency Virus; HIV Antigens; HIV Protease Inhibitors; HIV-1; Humans; Mutagenesis, Site-Directed; Virus Replication	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Amending HIV Drugs: A Novel Small-Molecule Approach To Target Lupus Anti-DNA Antibodies. Journal of medicinal chemistry, 2016, 10-13, Volume: 59, Issue:19 Topics: Animals; Antibodies, Antinuclear; DNA; Drug Discovery; Female; HIV Protease Inhibitors; Humans; Kidney Glomerulus; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB; Models, Molecular	2016
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. ACS medicinal chemistry letters, 2020, Dec-10, Volume: 11, Issue:12 Topics:	2020
When to switch and what to switch to: strategic use of antiretroviral therapy. The AIDS reader, 2000, Volume: 10, Issue:3 Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Mutation; Nelfinavir; Practice Guidelines as Topic; Pyrimidinones; Retroviridae; Retroviridae Infections; Reverse Transcriptase Inhibitors; Sulfonamides; Time Factors; Treatment Failure; Viral Load	2000
Kaletra versus nelfinavir. TreatmentUpdate, 2001,Spring, Volume: 12, Issue:12 Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Nelfinavir; Pyrimidinones; Ritonavir; Viral Load	2001
Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC. Clinical laboratory, 2001, Volume: 47, Issue:9-10 Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sulfonamides	2001
Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid- Therapeutic drug monitoring, 2002, Volume: 24, Issue:2 Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides	2002
Select HIV protease inhibitors alter bone and fat metabolism ex vivo. The Journal of biological chemistry, 2002, May-31, Volume: 277, Issue:22 Topics: Adipocytes; Animals; Animals, Newborn; Bone and Bones; Calcium; Carbamates; Cells, Cultured; Down-Regulation; Fats; Furans; Glycoproteins; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mesoderm; Nelfinavir; Osteoblasts; Osteoclasts; Osteoprotegerin; Pyrimidinones; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Ritonavir; Saquinavir; Skull; Stem Cells; Sulfonamides	2002
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma. Therapeutic drug monitoring, 2002, Volume: 24, Issue:3 Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Infections; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides	2002
Increasing choices for HIV therapy. The New England journal of medicine, 2002, Jun-27, Volume: 346, Issue:26 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir	2002
Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Therapeutic drug monitoring, 2003, Volume: 25, Issue:3 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; Heparin; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides	2003
Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors. AIDS patient care and STDs, 2003, Volume: 17, Issue:5 Topics: Adult; Arteriosclerosis; Biomarkers; Black People; C-Reactive Protein; Calcium; Cholesterol; Coronary Artery Disease; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Nelfinavir; Pyrimidinones; Ritonavir; Saquinavir	2003
pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS research and human retroviruses, 2003, Volume: 19, Issue:7 Topics: Adolescent; Adult; Africa, Western; Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Codon; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; Genes, pol; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sequence Alignment; Sequence Homology, Amino Acid; Sweden; Treatment Failure; Viremia; Zidovudine	2003
Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation. AIDS (London, England), 2003, Oct-17, Volume: 17, Issue:15 Topics: 3T3 Cells; Adipocytes; Animals; Carbamates; Cell Differentiation; Cell Line; Enzyme-Linked Immunosorbent Assay; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Mice; Mice, Inbred Strains; Nelfinavir; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides	2003
[Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance]. MMW Fortschritte der Medizin, 2003, Dec-11, Volume: 145, Issue:50 Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Time Factors; Viral Load	2003
Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART. Dermatology online journal, 2003, Volume: 9, Issue:5 Topics: Adult; Alopecia; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Nelfinavir; Pyrimidinones; Ritonavir; Stavudine	2003
Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir. Pharmacotherapy, 2004, Volume: 24, Issue:6 Topics: Adult; Anti-Retroviral Agents; Antidiarrheals; Antiretroviral Therapy, Highly Active; Cohort Studies; Diarrhea; Georgia; HIV Infections; Humans; Incidence; Lopinavir; Middle Aged; Nelfinavir; Pyrimidinones; Retrospective Studies; Ritonavir; United States; United States Department of Veterans Affairs	2004
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS (London, England), 2004, Nov-19, Volume: 18, Issue:17 Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Liver; Lopinavir; Male; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Saquinavir; Treatment Outcome	2004
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Jan-01, Volume: 40, Issue:1 Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Hepatitis; HIV Infections; Humans; Indinavir; Liver Function Tests; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine	2005
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi Therapeutic drug monitoring, 2005, Volume: 27, Issue:2 Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides	2005
Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations. The Journal of general virology, 2006, Volume: 87, Issue:Pt 5 Topics: Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Lopinavir; Microbial Sensitivity Tests; Mutation; Nelfinavir; Pyrimidinones; Species Specificity; Virus Replication	2006
Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS (London, England), 2006, Apr-24, Volume: 20, Issue:7 Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Blood Pressure; Body Mass Index; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Protease Inhibitors; Humans; Hypertension; Indinavir; Longitudinal Studies; Lopinavir; Male; Middle Aged; Nelfinavir; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir	2006
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. AIDS (London, England), 2006, Apr-24, Volume: 20, Issue:7 Topics: Carbamates; Codon; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Nelfinavir; Phenotype; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides	2006
Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir. The Annals of pharmacotherapy, 2006, Volume: 40, Issue:6 Topics: Anticonvulsants; Antiretroviral Therapy, Highly Active; Blood Cell Count; Carbamazepine; Drug Interactions; Drug Therapy, Combination; HIV Protease Inhibitors; HIV Seropositivity; Humans; Liver Function Tests; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Sleep Stages; Viral Load	2006
Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy. HIV medicine, 2006, Volume: 7, Issue:5 Topics: Adult; Antiretroviral Therapy, Highly Active; British Columbia; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Nelfinavir; Patient Compliance; Pyrimidinones; Ritonavir; Saquinavir; Viral Load	2006
Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Jan-01, Volume: 845, Issue:1 Topics: Atazanavir Sulfate; Calibration; Carbamates; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Fluorescence; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides; Ultraviolet Rays	2007
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clinical pharmacology and therapeutics, 2006, Volume: 80, Issue:4 Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Female; Genetic Variation; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Male; Middle Aged; Nelfinavir; Orosomucoid; Oxazines; Phenotype; Pyrimidinones; Ritonavir; Switzerland	2006
An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Apr-01, Volume: 848, Issue:2 Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet; Sulfonamides	2007
Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Dec-15, Volume: 43 Suppl 4 Topics: Adult; Buprenorphine; Case-Control Studies; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; HIV Protease Inhibitors; HIV Seronegativity; Humans; Lopinavir; Male; Narcotic Antagonists; Nelfinavir; Opioid-Related Disorders; Probability; Pyrimidinones; Reference Values; Risk Assessment; Ritonavir	2006
High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. Journal of pharmaceutical and biomedical analysis, 2007, Mar-12, Volume: 43, Issue:4 Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Structure; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Time Factors	2007
Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient. Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:7 Topics: Alopecia; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Treatment Outcome	2007
Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. Journal of medical virology, 2007, Volume: 79, Issue:11 Topics: Amino Acid Substitution; Databases, Protein; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Models, Molecular; Mutation; Nelfinavir; Pyrimidinones; Ritonavir; Spain; Treatment Failure	2007
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine. The Journal of infectious diseases, 2007, Dec-01, Volume: 196, Issue:11 Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Female; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Nelfinavir; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy	2007
Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. The Pediatric infectious disease journal, 2008, Volume: 27, Issue:5 Topics: Adolescent; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infant, Newborn; Longitudinal Studies; Lopinavir; Male; Nelfinavir; Pregnancy; Pyrimidinones; Ritonavir; Switzerland; Treatment Outcome; Viral Load; Withholding Treatment	2008
Possible antiretroviral therapy-warfarin drug interaction. Pharmacotherapy, 2008, Volume: 28, Issue:7 Topics: Adult; Anticoagulants; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Interactions; Humans; Lopinavir; Middle Aged; Nelfinavir; Nevirapine; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Warfarin	2008
Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens. Therapeutic drug monitoring, 2008, Volume: 30, Issue:5 Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Viral Load; Young Adult	2008
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin. Proteins, 2009, May-15, Volume: 75, Issue:3 Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides	2009
Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. Clinical chemistry, 2009, Volume: 55, Issue:1 Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Solid Phase Extraction; Sulfonamides	2009
Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation. Journal of computer-aided molecular design, 2009, Volume: 23, Issue:5 Topics: Amino Acid Sequence; Amino Acid Substitution; Catalytic Domain; Computer Simulation; Drug Design; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Models, Molecular; Molecular Sequence Data; Mutation; Nelfinavir; Protein Binding; Protein Conformation; Pyrimidinones; Thermodynamics	2009
HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis. PloS one, 2009, Volume: 4, Issue:3 Topics: AIDS-Related Opportunistic Infections; Animals; HIV Protease Inhibitors; Humans; Leishmania mexicana; Lopinavir; Macrophages; Nelfinavir; Protease Inhibitors; Pyrimidinones	2009
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Current HIV research, 2009, Volume: 7, Issue:6 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Atazanavir Sulfate; Birth Weight; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Lopinavir; Maternal-Fetal Exchange; Nelfinavir; Nevirapine; Oligopeptides; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyridines; Pyrimidinones	2009
Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS. Journal of molecular graphics & modelling, 2010, Volume: 28, Issue:5 Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Computational Biology; Cytochrome P-450 CYP3A; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides	2010
HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10 Topics: Atazanavir Sulfate; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Least-Squares Analysis; Lopinavir; Mutation; Nelfinavir; Oligopeptides; Organophosphates; Polymorphism, Genetic; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides	2010
HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS. Journal of molecular and cellular cardiology, 2010, Volume: 49, Issue:5 Topics: Action Potentials; Animals; Carbamates; Chloride Channels; Furans; HIV Integrase Inhibitors; HIV Protease Inhibitors; Ion Channel Gating; Lopinavir; Membrane Potential, Mitochondrial; Mitochondria; Myocytes, Cardiac; Nelfinavir; Pyrimidinones; Pyrrolidinones; Rabbits; Raltegravir Potassium; Reactive Oxygen Species; Ritonavir; Sulfonamides; Time Factors	2010
Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue. Journal of lipid research, 2011, Volume: 52, Issue:2 Topics: Adult; Atazanavir Sulfate; Carrier Proteins; Female; Gene Expression; HIV Protease Inhibitors; Humans; Inflammation; Interleukin-6; Intra-Abdominal Fat; Lopinavir; Male; Nelfinavir; Oligopeptides; Perilipin-1; Phosphoenolpyruvate Carboxykinase (GTP); Phosphoproteins; Pyridines; Pyrimidinones; Ritonavir; Sesquiterpenes; Subcutaneous Fat; Triglycerides; Tumor Necrosis Factor-alpha	2011
Genetic diversity of HIV type 1 in Montenegro. AIDS research and human retroviruses, 2011, Volume: 27, Issue:8 Topics: Adult; Antiretroviral Therapy, Highly Active; Base Sequence; Drug Resistance, Viral; Female; Genetic Variation; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Montenegro; Nelfinavir; Phylogeny; Population Surveillance	2011
The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2012, Volume: 7, Issue:2 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Atazanavir Sulfate; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; HIV Protease Inhibitors; Humans; Immunoblotting; Immunohistochemistry; Lopinavir; Macrophages; Mice; Mice, SCID; Mice, Transgenic; Nelfinavir; Neurons; Oligopeptides; Pyridines; Ritonavir; Saquinavir	2012
Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells. British journal of cancer, 2011, Aug-09, Volume: 105, Issue:4 Topics: Antibiotics, Antineoplastic; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Sarcoma, Kaposi; Treatment Outcome	2011
In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:11 Topics: Alkynes; Animals; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Carbamates; Cyclopropanes; Darunavir; Furans; Lopinavir; Nelfinavir; Nevirapine; Plasmodium falciparum; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides	2011
The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors. The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:4 Topics: Amino Acid Substitution; Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Lopinavir; Nelfinavir; Oligopeptides; Polymorphism, Genetic; Pyridines; Virus Cultivation	2012
Transplacental passage of nevirapine, nelfinavir and lopinavir. The Netherlands journal of medicine, 2012, Volume: 70, Issue:2 Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Female; Fetal Blood; HIV Infections; Humans; Lopinavir; Maternal-Fetal Exchange; Nelfinavir; Nevirapine; Pregnancy	2012
Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs. Biopharmaceutics & drug disposition, 2013, Volume: 34, Issue:3 Topics: Carbamates; Cells, Cultured; Drug Interactions; Furans; Hepatocytes; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Organic Anion Transporters; Ritonavir; Sulfonamides	2013
Targeting cancer stem cells expressing an embryonic signature with anti-proteases to decrease their tumor potential. Cell death & disease, 2013, Jul-04, Volume: 4 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Disease Progression; Drug Screening Assays, Antitumor; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Intestinal Neoplasms; Lopinavir; Mesenchymal Stem Cells; Mice; Mice, SCID; Nelfinavir; Neoplasm Transplantation; Neoplastic Stem Cells; Pyrans; Structure-Activity Relationship; Tumor Cells, Cultured	2013
Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. Leukemia research, 2014, Volume: 38, Issue:3 Topics: Apoptosis; Cytotoxins; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Leukemic; HIV Protease Inhibitors; Humans; Leukemia, Myeloid, Acute; Lopinavir; Nelfinavir; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Ritonavir; Saquinavir; Signal Transduction; Tumor Cells, Cultured	2014
Antiretroviral protease inhibitors accelerate glutathione export from viable cultured rat neurons. Neurochemical research, 2014, Volume: 39, Issue:5 Topics: Cells, Cultured; Glutathione; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Neurons; Ritonavir	2014
Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model. PloS one, 2014, Volume: 9, Issue:12 Topics: Animals; Anti-HIV Agents; Aspartic Acid Proteases; Carbamates; Furans; Host-Parasite Interactions; Indinavir; Insect Vectors; Lopinavir; Microscopy, Electron, Transmission; Nelfinavir; Protease Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Trypanocidal Agents; Trypanosoma cruzi	2014
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART). Current molecular medicine, 2015, Volume: 15, Issue:10 Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine	2015
Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4. PloS one, 2016, Volume: 11, Issue:1 Topics: Amphetamine-Related Disorders; Atazanavir Sulfate; Catalytic Domain; Cytochrome P-450 CYP3A; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Inactivation, Metabolic; Lopinavir; Methamphetamine; Microsomes, Liver; Molecular Docking Simulation; Nelfinavir; Protein Binding; Pyridines; Pyrones; Sulfonamides	2016
Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir. Infectious diseases in obstetrics and gynecology, 2016, Volume: 2016 Topics: Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Infant, Newborn; Infant, Newborn, Diseases; Lopinavir; Male; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Retrospective Studies; Ritonavir	2016
Nelfinavir and lopinavir impair Trypanosoma cruzi trypomastigote infection in mammalian host cells and show anti-amastigote activity. International journal of antimicrobial agents, 2016, Volume: 48, Issue:6 Topics: Animals; Antiprotozoal Agents; Aspartic Acid Proteases; Cell Line; Cell Survival; Cytoplasm; Drug Repositioning; Lopinavir; Macaca mulatta; Mice; Nelfinavir; Trypanosoma cruzi	2016
Deciphering the effects of nelfinavir and lopinavir on epimastigote forms of Trypanosoma cruzi. Parasitology international, 2017, Volume: 66, Issue:5 Topics: Aspartic Acid Proteases; Cell Membrane; Flagella; HIV Protease Inhibitors; Lethal Dose 50; Lopinavir; Microscopy, Electron, Scanning; Microscopy, Fluorescence; Microscopy, Interference; Mitochondria; Nelfinavir; Oxidoreductases; Permeability; Proteasome Endopeptidase Complex; Trypanocidal Agents; Trypanosoma cruzi	2017
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia, 2018, Volume: 32, Issue:2 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; HIV Protease Inhibitors; Humans; Lopinavir; Multiple Myeloma; Nelfinavir; Oligopeptides; Plasma Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors	2018
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PloS one, 2017, Volume: 12, Issue:7 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV-1; Lamivudine; Lopinavir; Nelfinavir; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine	2017
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU international, 2018, Volume: 121, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; HIV Protease Inhibitors; Humans; Kidney Neoplasms; Lopinavir; Nelfinavir; Proteasome Inhibitors	2018
Primary evidence of the mechanisms of action of HIV aspartyl peptidase inhibitors on Trypanosoma cruzi trypomastigote forms. International journal of antimicrobial agents, 2018, Volume: 52, Issue:2 Topics: Cell Membrane; Endoplasmic Reticulum; Flagella; HIV Protease Inhibitors; Life Cycle Stages; Lipid Droplets; Lopinavir; Mitochondria; Mitochondrial Swelling; Nelfinavir; Oxidoreductases; Parasitic Sensitivity Tests; Protozoan Proteins; Reactive Oxygen Species; Trypanosoma cruzi	2018
Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition. Anticancer research, 2019, Volume: 39, Issue:7 Topics: Antimitotic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fluphenazine; Furans; HIV Protease Inhibitors; Humans; Ketones; Lopinavir; Mouth Neoplasms; Nelfinavir; Ritonavir; Vincristine	2019
The integrated stress response promotes B7H6 expression. Journal of molecular medicine (Berlin, Germany), 2020, Volume: 98, Issue:1 Topics: B7 Antigens; Blood Donors; Cell Line, Tumor; eIF-2 Kinase; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; HIV Protease Inhibitors; Humans; Immunotherapy, Adoptive; Killer Cells, Natural; Lopinavir; Nelfinavir; Phosphorylation; Receptors, Chimeric Antigen; Signal Transduction; T-Lymphocytes; Transduction, Genetic; Transfection; Unfolded Protein Response	2020
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation. Scientific reports, 2020, 10-12, Volume: 10, Issue:1 Topics: Betacoronavirus; Binding Sites; Biophysical Phenomena; Catalytic Domain; Computational Biology; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Darunavir; Drug Repositioning; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Dynamics Simulation; Nelfinavir; Pandemics; Pneumonia, Viral; Ritonavir; Saquinavir; SARS-CoV-2; Viral Nonstructural Proteins	2020
Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir. Scientific reports, 2020, 12-01, Volume: 10, Issue:1 Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Drug Combinations; Drug Discovery; Drug Repositioning; Humans; Lopinavir; Molecular Dynamics Simulation; Nelfinavir; Protease Inhibitors; Ritonavir; SARS-CoV-2	2020
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clinical pharmacology and therapeutics, 2021, Volume: 110, Issue:4 Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Contraceptive Agents, Hormonal; Contraceptive Effectiveness; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Lopinavir; Medroxyprogesterone Acetate; Nelfinavir; Rifampin; Ritonavir; Tuberculosis	2021
Decoding molecular mechanism underlying binding of drugs to HIV-1 protease with molecular dynamics simulations and MM-GBSA calculations. SAR and QSAR in environmental research, 2021, Volume: 32, Issue:11 Topics: Anti-HIV Agents; Atazanavir Sulfate; Binding Sites; HIV Protease; Lopinavir; Molecular Dynamics Simulation; Nelfinavir	2021
HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. Antiviral research, 2022, Volume: 202 Topics: Animals; COVID-19 Drug Treatment; Cricetinae; HIV Infections; HIV Protease Inhibitors; Lopinavir; Lung; Mesocricetus; Nelfinavir; Ritonavir; RNA, Viral; SARS-CoV-2	2022